Vastardis Iraklis, Pajic-Eggspuehler Brigitte, Nichorlis Charis, Mueller Jörg, Pajic Bojan
Swiss Eye Research Foundation, Eye Clinic ORASIS, Titlisstrasse 44, 5734 Reinach, Switzerland.
University of Novi Sad, Faculty of Physics, Novi Sad, Serbia.
Open Ophthalmol J. 2017 Jul 31;11:217-224. doi: 10.2174/1874364101711010217. eCollection 2017.
The introduction of corneal cross-linking (CXL) with ultraviolet-A (UVA) and Riboflavin photosensitizer (Vit B) from Seiler , revolutionized the treatment of Keratoconus and other corneal ectatic diseases. Today, the commonly known epithelium off Dresden protocol is in clinical use for the last 15 years with great success and regarded by many as the golden standard.
With several studies demonstrating its simplicity, efficacy and safety this revolutionary method, paved the way for new therapies and strategies in the treatment of corneal ectatic diseases and changed our understanding in corneal biomechanics. Recent scientific and technological advances enabled the creation of various modifications of the initial CXL protocol and the formation of new ones.
This work highlights the recent advances of CXL, such as the role of oxygen, higher fluence and shorter irradiation times as well as the various clinical applications and updates of this method.
塞勒引入的紫外线A（UVA）和核黄素光敏剂（维生素B）角膜交联（CXL）技术，彻底改变了圆锥角膜和其他角膜扩张性疾病的治疗方法。如今，广为人知的德累斯顿去上皮方案已在临床应用了15年，取得了巨大成功，被许多人视为金标准。
多项研究证明了这种革命性方法的简便性、有效性和安全性，为角膜扩张性疾病的新治疗方法和策略铺平了道路，并改变了我们对角膜生物力学的认识。最近的科技进步使得能够对最初的CXL方案进行各种改进并形成新的方案。
本文重点介绍了CXL的最新进展，如氧气的作用、更高的能量密度和更短的照射时间，以及该方法的各种临床应用和更新情况。
